A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Emotional lability
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results (n=253) assessing prolonged effectiveness of Dextromethorphan Hydrobromide/Quinidine Sulfate presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 03 May 2014 Results of a post-hoc analysis (n=216) presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2014 The results of a post-hoc analysis were presented at the 66th Annual Meeting of the American Academy of Neurology (AAN) in April 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top